Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2000, for AVI BioPharma, Inc. (Note: The input metadata referenced Sarepta Therapeutics, but the filing text explicitly identifies the registrant as AVI BioPharma, Inc.). The company is a development-stage biopharmaceutical firm focused on research and development (R&D) with no material product sales. It has been unprofitable since its inception in July 1980.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2000 | Six Months Ended June 30, 2000 | As of June 30, 2000 |
|---|---|---|---|
| Revenues | $18,250 | $1,150,123 | - |
| Net Loss | $(2,840,413) | $(3,980,295) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.17) | $(0.24) | - |
| Cash and Cash Equivalents | - | - | $6,949,190 |
| Short-term Securities | - | - | $3,625,000 |
| Total Current Assets | - | - | $10,597,332 |
| Total Current Liabilities | - | - | $1,104,596 |
| Accumulated Deficit | - | - | $(55,034,172) |
Operating Expenses: Total operating expenses for the six months ended June 30, 2000, were $5,346,663, driven primarily by Research and Development ($4,420,415) and General and Administrative costs ($926,248).
Material Changes vs. Prior Period
- Revenue Growth: Revenues for the six months ended June 30, 2000, increased to $1,150,123 from $4,225 in the prior year period. This increase was primarily due to a $1,000,000 license fee received in the first quarter from an agreement modification with AGDG regarding diagnostic applications.
- Expense Increases: Operating expenses rose to $5,346,663 for the six-month period (from $3,867,957 in 1999) due to increased R&D staffing, outside collaborations, and pre-clinical/clinical testing costs.
- Cash Position: Cash and cash equivalents decreased by $1,733,815 to $6,949,190 compared to December 31, 1999, reflecting higher operational burn rates partially offset by option exercises and the license fee.
- Interest Income: Net interest income increased to $216,245 for the six months ended June 30, 2000, from $127,088 in the prior year, attributable to earnings on higher cash balances.
Outlook, Risks, and Subsequent Events
- SuperGen Alliance: In April 2000, the company entered an alliance with SuperGen, Inc. for shared development of Avicine. Upon closing (expected Q3 2000), AVI is to receive $5,000,000 cash and SuperGen stock in exchange for AVI stock and warrants.
- Secondary Offering: In July 2000, the company completed a secondary offering of 3,000,000 shares at $7.25 per share, with net proceeds of approximately $20,000,000. An over-allotment option could raise an additional $3,000,000.
- Liquidity: Management expects existing cash resources to satisfy requirements for the next 24 months. However, the company anticipates continued losses and increasing cash requirements as R&D expands.
- Risks: The company faces significant risks regarding the success of clinical trials, regulatory approvals (FDA), and the ability to generate product revenue. There is no assurance of future profitability.
Investor Verification Checklist
- Verify the closing status and final terms of the SuperGen, Inc. alliance and the receipt of the $5,000,000 cash payment.
- Confirm the final net proceeds from the July 2000 secondary offering, including whether the over-allotment option was exercised.
- Monitor the progress of pre-clinical and clinical trials for Avicine and other technologies to assess future capital needs.
- Review the impact of the AGDG license fee modification on future royalty streams and revenue recognition.
- Assess the burn rate relative to the $6.9 million cash balance to validate the 24-month liquidity runway.